Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the effect of quercetin on glucose tolerance and
postprandial endothelial function in comparison to placebo and Acarbose in participants with
Type 2 Diabetes.
Primary Hypothesis: We hypothesize that administration of quercetin (2g oral) prior to a 100g
maltose tolerance test (MTT) will result in a decrease in postprandial blood glucose at 60
minutes compared to placebo. Acarbose (100mg oral), a pharmaceutical alpha-glucosidase
inhibitor, will serve as a positive control.
Secondary Hypothesis: We hypothesize that administration of quercetin (2g oral) will reduce
the Area Under the Glucose Curve (AUC) for the 2 hours following a 100g MTT compared to
placebo. AUC is hypothesized to be comparable between quercetin and Acarbose.
Tertiary hypothesis: We hypothesize that administration of quercetin (2g oral) prior to a
100g MTT will result in a smaller reduction in flow mediated dilation (FMD) measured as an
increase in Reactive Hyperemia Index (RHI) at 90 minutes compared to placebo.